Dossier assessment
Talazoparib (breast cancer) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Talazoparib (breast cancer) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Talazoparib (breast cancer) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Indication:
| Adults with BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer |
Result of dossier assessment:
| Hint of considerable added benefit |
Press releases
Talazoparib in breast cancer: hint of considerable added benefit
Advantages in health-related quality of life, symptoms and side effects outweigh disadvantages
Additional information
Federal Joint Committee (G-BA)
20.11.2020 A G-BA decision was published.
Project details
- Project no.
- A20-48
- Commission
- Commission awarded on 29.05.2020 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
Connected Projects
-
Dossier assessment
Talazoparib (prostate cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed